Literature DB >> 31632566

MiR-27b targets PI3K p110α to inhibit proliferation and migration in colorectal cancer stem cell.

Yun Chen1, Bing Zhang1, Ye Jin1, Qi Wu1, Lifang Cao1.   

Abstract

Colorectal cancer (CRC) is one of the leading causes of cancer deaths worldwide, CRC was estimated to be the third most commonly diagnosed cancer and a leading cause of cancer deaths in developed countries due to therapy resistance and metastasis. Cancer stem cells (CSCs) were found in a variety of malignant tumors, including colorectal cancer. miR-27b play pivotal roles in the acquisition of CSC properties such as tumor initiation, drug resistance and asymmetric cell division. The aim of the present study was to investigate the underlying mechanisms that miR-27b inhibits proliferation, invasion and migration of CSCs. In present study, miR-27b were found to be significantly upregulated in CSCs. Overexpression of miR-27b inhibit CSCs proliferation and migration. In addition, overexpression of miR-27b suppress the character expression of CSCs, including of CD44, CD133, Sox2 and Oct4. Furthermore, it has been demonstrated that miR-27b is directly targeted by PIK3CA and miR-27b overexpression can effectively attenuate the expression of Phosphor-PI3K p110α and phosphor-Akt. In conclusion, these results reveal that PIK3CA is significantly downregulated by miR-27b expression in CSCs. Thus, we presume that miR-27b may be a therapeutic anti-tumor agent for CRC via targeting PI3K p110α. AJTR
Copyright © 2019.

Entities:  

Keywords:  MiR-27b; PI3K p110α; colorectal cancer; migration; proliferation

Year:  2019        PMID: 31632566      PMCID: PMC6789227     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  28 in total

1.  Colorectal cancer statistics, 2014.

Authors:  Rebecca Siegel; Carol Desantis; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2014-03-17       Impact factor: 508.702

2.  MicroRNA-328-3p inhibits the tumorigenesis of bladder cancer through targeting ITGA5 and inactivating PI3K/AKT pathway.

Authors:  T Yan; X-X Ye
Journal:  Eur Rev Med Pharmacol Sci       Date:  2019-06       Impact factor: 3.507

3.  Direct reprogramming of stem cell properties in colon cancer cells by CD44.

Authors:  Ying-Jhen Su; Hsin-Mei Lai; Yi-Wen Chang; Guan-Ying Chen; Jia-Lin Lee
Journal:  EMBO J       Date:  2011-06-24       Impact factor: 11.598

4.  Functional analysis of PIK3CA gene mutations in human colorectal cancer.

Authors:  Tsuneo Ikenoue; Fumihiko Kanai; Yohko Hikiba; Toshiyuki Obata; Yasuo Tanaka; Jun Imamura; Miki Ohta; Amarsanaa Jazag; Bayasi Guleng; Keisuke Tateishi; Yoshinari Asaoka; Masayuki Matsumura; Takao Kawabe; Masao Omata
Journal:  Cancer Res       Date:  2005-06-01       Impact factor: 12.701

5.  Identification and expansion of human colon-cancer-initiating cells.

Authors:  Lucia Ricci-Vitiani; Dario G Lombardi; Emanuela Pilozzi; Mauro Biffoni; Matilde Todaro; Cesare Peschle; Ruggero De Maria
Journal:  Nature       Date:  2006-11-19       Impact factor: 49.962

Review 6.  PI3K pathway alterations in cancer: variations on a theme.

Authors:  T L Yuan; L C Cantley
Journal:  Oncogene       Date:  2008-09-18       Impact factor: 9.867

7.  Identification and characterization of ovarian cancer-initiating cells from primary human tumors.

Authors:  Shu Zhang; Curt Balch; Michael W Chan; Hung-Cheng Lai; Daniela Matei; Jeanne M Schilder; Pearlly S Yan; Tim H-M Huang; Kenneth P Nephew
Journal:  Cancer Res       Date:  2008-06-01       Impact factor: 12.701

8.  MEK5/ERK5 activation regulates colon cancer stem-like cell properties.

Authors:  Diane M Pereira; Sofia E Gomes; Pedro M Borralho; Cecília M P Rodrigues
Journal:  Cell Death Discov       Date:  2019-02-11

9.  Long non-coding RNA PCAT-1 promotes tumor progression by inhibiting miR-129-5p in human ovarian cancer.

Authors:  Li-Ping Gu; Shuo Jin; Rong-Chun Xu; Jing Zhang; Ying-Chun Geng; Xing-Yue Shao; Li-Bo Qin
Journal:  Arch Med Sci       Date:  2018-04-30       Impact factor: 3.318

10.  Protein arginine methyltransferase 8 gene enhances the colon cancer stem cell (CSC) function by upregulating the pluripotency transcription factor.

Authors:  Haishan Lin; Bin Wang; Jing Yu; Jing Wang; Qin Li; Bangwei Cao
Journal:  J Cancer       Date:  2018-04-06       Impact factor: 4.207

View more
  7 in total

1.  LINC01234 regulates microRNA-27b-5p to induce the migration, invasion and self-renewal of ovarian cancer stem cells through targeting SIRT5.

Authors:  Fang Ke; Chenchen Ren; Zihan Zhai; Xiang Gao; Jing Wei; Yuanhang Zhu; Yunxiao Zhi
Journal:  Cell Cycle       Date:  2022-03-01       Impact factor: 5.173

2.  lncRNA TTN‑AS1 upregulates RUNX1 to enhance glioma progression via sponging miR‑27b‑3p.

Authors:  Keliang Chang; Genwei Wang; Jinfeng Lou; Sha Hao; Ranbo Lv; Desheng Duan; Wanhong Zhang; Yingchang Guo; Pengfei Wang
Journal:  Oncol Rep       Date:  2020-07-10       Impact factor: 3.906

3.  MicroRNA-196b-5p promotes malignant progression of colorectal cancer by targeting ING5.

Authors:  He Xin; Chuanzhuo Wang; Yuan Chi; Zhaoyu Liu
Journal:  Cancer Cell Int       Date:  2020-04-10       Impact factor: 5.722

4.  LncRNA LINC00511 Acts as an Oncogene in Colorectal Cancer via Sponging miR-29c-3p to Upregulate NFIA.

Authors:  Yu Hu; Ying Zhang; Meng Ding; Ruisi Xu
Journal:  Onco Targets Ther       Date:  2021-01-05       Impact factor: 4.147

5.  MSI1 Promotes the Expression of the GBM Stem Cell Marker CD44 by Impairing miRNA-Dependent Degradation.

Authors:  Rebecca Pötschke; Jacob Haase; Markus Glaß; Sebastian Simmermacher; Claudia Misiak; Luiz O F Penalva; Caspar D Kühnöl; Stefan Hüttelmaier
Journal:  Cancers (Basel)       Date:  2020-12-05       Impact factor: 6.639

6.  Sevoflurane inhibits cell proliferation and migration of glioma by targeting the miR‑27b/VEGF axis.

Authors:  Xi Zhan; Changcheng Lei; Linzhu Yang
Journal:  Mol Med Rep       Date:  2021-03-31       Impact factor: 2.952

7.  Effects of hsa-miR-28-5p on Adriamycin Sensitivity in Diffuse Large B-Cell Lymphoma.

Authors:  Shufang Yan; Qinyu Shang; Haipeng Zhu; Ken Chen; Xinxia Li; Hongliang Gao; Bo Liu; Mei Feng; Lixia Gao
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-13       Impact factor: 2.650

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.